From Nasdaq: 2025-01-21 05:47:00

Novo Nordisk’s Ozempic and Wegovy have become blockbuster drugs after FDA approval for treating type 2 diabetes and chronic weight management. However, Medicare’s plan for 2027 drug price negotiations could impact Novo Nordisk’s growth, with the potential for significant price cuts. Investors reacted negatively to the news, causing Novo Nordisk’s stock to drop over 5%. The impact of Medicare negotiations on Novo Nordisk’s revenue will depend on the final negotiated prices. Despite this, Novo Nordisk’s opportunity for growth remains significant, especially with potential new drugs in development. President Trump’s promise to repeal the IRA could also affect Medicare negotiations.



Read more at Nasdaq: Will Medicare End Ozempic Maker Novo Nordisk’s Obesity Drug Boom?